Last reviewed · How we verify
randomization between two established Chemotherapies
This is a randomized clinical trial comparing two established chemotherapy regimens rather than a single drug entity.
At a glance
| Generic name | randomization between two established Chemotherapies |
|---|---|
| Sponsor | Technische Universität Dresden |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
This entry describes a study design (randomization between two chemotherapies) rather than a discrete pharmaceutical product. The specific mechanisms depend on which two chemotherapy agents are being compared in the trial. Without identification of the particular chemotherapies involved, a mechanistic description cannot be accurately provided.
Approved indications
Common side effects
Key clinical trials
- The Influence of Chemotherapy on Position Sense
- A Mixed Methods Study of Nutrition Practice in Cancer Care on Non-Hodgkin Lymphoma Population (NA)
- Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children (PHASE2, PHASE3)
- Comparing Interventions for Opioid Dependent Patients Presenting in Medical Emergency Departments (NA)
- Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: